NCT06648525: Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
- State
- Not started
- Phase
- Phase 2
- People
- 68 planned
- Started
- Oct 2024
- Primary completion
- Apr 2027
- Arms
- Group A: Adebrelimab+Irinotecan liposomes+5-fluorouracil+calcium folinate+lenvatinib
- Results
- None posted
- 18 Oct 2024: Trial registered